EMA Authorised: Buccolam (midazolam) — Neuraxpharm Pharmaceuticals S.L.

View source ↗

Summary

The EMA authorised Buccolam, a midazolam product, for treatment of epileptic seizures; the marketing authorization holder is Neuraxpharm Pharmaceuticals S.L. (d…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epilepsy

Drugs mentioned

• Buccolam (midazolam)

Snippet

Status: Authorised. Therapeutic area: Epilepsy. MAH: Neuraxpharm Pharmaceuticals S.L.. Decision date: 21/10/2024